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 re-hospitalization  (Weiden et al., 2004). If this lack of insight 
into the need for treatment extends to cognitive symptoms as 
well, then this will have a huge impact on how it is managed, 
and affect all stages of the process from referral, to monitoring 
progress, and assessing improvement.
One way to assess patient insight into their cognitive defi-
cits is to use subjective scales, and since the first mention of 
these “basic symptoms” by Huber (1957), several such instru-
ments have been developed and tested for validity with objective 
neuro-cognitive tests.
The subjective scale to investigate cognition in schizophrenia 
(SSTICS) was developed by our research center and published by 
Stip et al. (2003). The design aim was to develop a simple and eco-
logical scale to assess patients’ subjective experiences of cognitive 
impairment as indicated from objective tests. The scale eventually 
consisted of 21 Likert-type questions set in the context of everyday 
activities and situations.
This review aims to give an up-to-date account of studies which 
have used scales of subjective cognitive deficits in schizophrenia 
alongside objective assessments of cognition. In accessing the 
degree of correlation between subjective and objective tests we 
focus on the question of whether schizophrenic patients are just 
as hindered in their insight into their cognitive dysfunction as in 
their illness overall. If indeed patient insight is less affected in the 
domain of cognition, therapies targeted in this area could theoreti-
cally increase compliance and thus patient outcome. Designers of 
clinical trials measuring the effectiveness of schizophrenia treat-
ments in general may wish to incorporate measures of cognitive 
dysfunction into their study. And so, better understanding of the 
relationship between subjective and objective measures of cogni-
tive dysfunction in schizophrenia will also serve to help guide the 
choice of clinical trial outcome measures.
Background
The presence of cognitive dysfunction in patients with schizo-
phrenia has long been recognized (O’Carroll, 1992; Heinrichs 
and Zakzanis, 1998; Fioravanti et al., 2005), notably in the areas 
of attention, memory and executive function (Gold and Harvey, 
1993). They are found in up to 75% of patients (Goldberg et al., 
1998) and are a frequent source of complaint, leading patients 
to score themselves higher on subjective questionnaires of cog-
nitive dysfunction than healthy controls (Moritz et al., 2001). 
Cognitive deficits are a major contributor to the functional and 
social impairment suffered by schizophrenic patients (Addington 
and Addington, 1999; Bell and Bryson, 2001; Hofer et al., 2005) 
and have been noted to have more of an impact on daily life than a 
patient’s positive and negative symptoms (Green, 1996). Cognitive 
dysfunction in schizophrenia is generally associated with a poor 
outcome (Green et al., 2000; Bodnar et al., 2008), which has led to 
the development of cognition targeted treatments such as phar-
macological agents, aided by the National Institute of Mental 
Health initiative entitled “measurement and treatment research 
to improve cognition in schizophrenia” (MATRICS; Marden and 
Fenton, 2004).
It has also been well documented that patients with schizo-
phrenia have a specifically poor level of insight into their condi-
tion in comparison to other mental health disorders (Amador 
et al., 1994; Pini et al., 2001), affecting approximately 30–80% of 
patients (Amador and Gorman, 1998; Cuesta et al., 2000). Poor 
insight is again linked to poor clinical outcome and also con-
tributes to compliance (Smith et al., 1999; Buckley et al., 2007). 
Medication non-compliance is estimated to be at a level of 42% 
in the schizophrenic population (Cramer and Rosenheck, 1998) 
and is associated with a wide range of adverse consequences 
such an increased risk of relapse (Fenton et al., 1997) and 
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A search within MEDLINE, psychINFO, and Web of Science using 
the criteria “subjective, cognition, schizophrenia” was performed. 
After filtering and cross-referencing, a total of 26 articles were found 
which used a scale to assess subjective cognitive dysfunction in 
schizophrenia patients and then compared scores to objective meas-
ures. The SSTICS was the most frequently used scale, being found 
in 10 of the 26 studies.
Findings
A total of 14 different scales that have been used to assess subjective 
cognitive dysfunction in schizophrenia patients were identified from the 
literature search and summarized in Table 1. Twelve of the scales were 
self-rated and two were interview based, seven were designed for patients 
with schizophrenia, one for patients with psychosis, one for those with 
known cognitive deficits, and five were designed for a non-specific 
patient group. Eleven scales covered more than one cognitive domain.
Table 1 | subjective scales to assess cognitive dysfunction.
Scale name Authors Population Design Areas covered
Subjective scale to 
investigate cognition in 
schizophrenia (SSTICS)
Stip et al. 
(2003)
Schizophrenia 
patients
Self-rated 21 Likert-type 
questions
Memory, attention, executive function, 
praxia, language 
Measure of insight into 
cognition-self-rated (MIC-SR)
Medalia et al. 
(2008)
Schizophrenia 
patients 
Self-rated, 12 items rated on a 
scale of frequency 0–3
Attention, memory, executive functioning
Measure of insight into 
cognition- clinician-rated 
(MIC-CR)
Medalia and 
Thysen (2008)
Schizophrenia 
patients
Interview, 12 questions, scale 
1–5
Attention, memory, executive functioning 
Schizophrenia cognition 
rating scale (SCoRS)
Keefe et al. 
(2006)
Schizophrenia 
patients
Interview 18 items, 4 point 
scale. Three scores, generated 
from patient, informant and 
interviewer rating.
Attention, memory, reasoning and problem 
solving, working memory, language 
production, motor skills. 
Subjective perception of 
attention improvement 
questionnaire (SPAIQ)
López-Luengo 
(2000)
Schizophrenia 
patients 
Self-rated, 7 point Likert scale  Attention 
Eppendorf schizophrenia 
inventory (ESI)
Mass (2000) Schizophrenia 
patients
Self-rated, 138 items, 4 
subscales, on a 4 point Likert 
scale
Attention and speech impairment (AS), 
ideas of reference (IR), auditory uncertainty 
(AU), deviant perception (DP).
Frankfurt complaint 
questionnaire (FCQ)
Süllwold 
(1977)
Schizophrenia 
patients
Self-rated, 98 yes/no questions 10 subscales in four factors of: central 
cognitive disturbances, perception and 
motility, depressivity, internal and external 
overstimulation 
Work-readiness cognitive 
screen (WCS)
Erlanger and 
Feldman 
(2002)
Populations with 
known or suspected 
cognitive dysfunction 
Self-rated, web based, 10-point 
Likert scale, clinician-rated on 5 
point scale
Vocational preferences, work values, 
self-confidence in attention, memory, 
working, and socializing. 
Questionnaire for self-
experienced deficits of 
attention (FEDA)
Zimmerman 
et al. (1991)
Non-specific  Self-rated, 76 items with 5 
point Likert scale.
Attention-divided, selective memory-
prospective, long term, forgetting 
medicines, remembering names. 
Test of Attentional Style (TAS) van den Bosch 
et al. (1993)
Non-specific  Self-report, 31 items, 5 
subscales
Attention in everyday life-distractibility, 
overload, processing capacity, attentional 
control, conceptual control 
Prospective and retrospective 
memory questionnaire 
(PRMQ)
Smith et al. 
(2000)
Non-specific  Self-rated, 16 items rated on a 
5 point Likert scale. 
Memory
Dysexecutive questionnaire 
(DEX)
Wilson et al. 
(1996)
Non-specific  Self-rated 20 items, rate the 
frequency of occurrence
Dysexecutive characteristics 
Cognitive failures 
questionnaire (CFQ)
Broadbent 
et al. (1982)
Non-specific  Self-rated, 25 items, 5 point 
Likert scale
Daily cognitive failures such as forgetting 
names, confusing left and right. 
Patient perception of 
functioning scale (PPFS)
Ehmann et al. 
(2007)
Psychotic patients  Self-rated, six items on a 5 
point Likert scale
Concentration, conversational ability, 
thinking clearly, handling money, carrying 
out everyday tasks, memory 
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et al., 1987), but no significant correlations were found. Medalia 
et al. (2008) found no correlation between MIC-SR score and the 
PANSS question on insight and Medalia and Thysen (2008) found 
that half of the patients in their study using the MIC-CR had no 
awareness of their cognitive deficit and 39% of those that did have 
some awareness were not able to attribute this to mental illness. 
In Medalia and Thysen (2010) found that 70% of patients had full 
insight into their clinical symptoms, whereas only 27% had full 
insight into their cognitive symptoms, coming to the conclusion 
that the issue of insight in schizophrenia is not a unitary concept.
Indeed, Osatuke et al. (2008) point out in their review on the 
topic of insight in schizophrenia that the issue is far from straight 
forward. In terms of definition, research suggests that it should 
be regarded as a continuum, rather than something that a patient 
either does or does not have (Markova and Berios, 1995). It is also 
multidimensional, meaning that patients can have awareness of 
not just the presence of an illness, but also the consequences and 
need for treatment (Amador and David, 1998). And to further 
complicate the matter, insight has been recognized to vary within 
an individual in terms of different clinical aspects of the illness 
(Peralta and Cuesta, 1994) and even along the course of the disease 
(Kemp and Lambert, 1995). The reviewers also discuss the many 
proposed aetiological models of insight in schizophrenia such as it 
being a defense mechanism, or included as a positive or even nega-
tive symptom. They also touch on theories surrounding, neuro-
cognitive deficits as well as an impairment of metacognition, or in 
other words, the ability to think about thinking, both in terms of 
oneself and others.
Proponents of the theory that neuro-cognitive deficits play 
a central role in the lack of insight into illness in schizophrenia, 
focus particularly on frontal and parietal dysfunction (David, 
1999). Indeed there have been associations with the Wisconsin 
card-sorting test and poor insight (Young et al., 2003) and Drake 
and Lewis (2003) showed that perseveration was strongly linked 
to poor insight. Smith et al. (2000) found that symptom misattri-
bution was correlated with card-sorting measures of frontal lobe 
function although symptom unawareness was largely unrelated 
to neuro-cognitive functioning, which led them to conclude that 
insight in schizophrenia is a multidimensional construct. McEvoy 
et al. (1996) found that the insight and treatment attitudes ques-
tionnaire (ITAQ) score was significantly correlated to only one 
of nine measures of performance on neuro-cognitive tasks, and 
Medalia and Thysen (2010) found that only performance on the 
BACS Tower of London Task was correlated with clinical insight. 
In addition, Donohoe et al. (2009) found that although subjective 
and objective tests of cognitive dysfunction only correlated in the 
patients with intact clinical insight, just 33% of those with poor 
clinical insight also had poor cognitive insight, again indicating 
that these two types of insight are fundamentally different in their 
nature.
In an attempt to clarify this idea that insight into cognitive 
dysfunction could be distinct from overall insight into schizo-
phrenia, the term “schizoanosognosia” was coined by Stip (2006). 
Anosognosia derives from the Greek words for disease (nosos) and 
knowledge (gnosis) and is a term similar in definition to insight and 
A summary of the 26 studies using these scales and comparing 
results to objective cognitive tests is presented in Table 2. The results 
are unclear, with 12 of the 26 studies lending support to the idea 
that insight into cognitive deficits in schizophrenia is intact, whereas 
14 suggest that cognition is no different from other schizophre-
nia symptoms in terms of insight. In the four cases where a scale 
was used in more than one study, all verdicts pointed in the same 
direction for two scales, but four of the 10 studies with the SSTICS 
differed in their conclusions, and one of three did with the FCQ.
Overall, a wide variety of objective tests of cognition were used 
to compare against subjective scores, ranging from using the cogni-
tive question on the positive and negative symptom scale interview 
(PANSS; Kay et al., 1987) to the pencil and paper brief assessment of 
cognition in schizophrenia (BACS; Keefe et al., 2004) and computer 
based neuropsychological batteries such as Cambridge neuropsy-
chological test automated battery (CANTAB; Fray et al., 1996).
concLusion
The aim of this paper was to review the literature on the use of 
subjective scales to assess cognitive deficits in schizophrenia and to 
see if these scales could predict results on objective tests. Overall, 
the findings were inconclusive, with approximately half of the stud-
ies supporting the hypothesis and half not. The individual scales 
however did yield the same outcome in half of the cases where the 
same scale was used more than once, although this is difficult to 
interpret due to a small number of studies, except the SSTICS which 
was used in 10 studies on this topic and showed a correlation with 
subjective and objective measures of cognitive deficit in six of these.
A number of the studies also included rater and clinician scores 
of the patient’s cognitive dysfunction, and interestingly it seems 
that as well as the inconclusive findings about the patients’ ability 
to correctly estimate their level of cognitive impairment, the ability 
of raters and clinician to do this is also variable. Keefe et al. (2006) 
found that the interviewer score on the SCoRS was correlated to 
objective tests, even though the informant and patient scores were 
not. However Moritz et al. (2004) found that in 20–40% of cases, 
clinicians rated the patient’s memory as normal even though they 
had significant impairment. López-Luengo and Vázquez (2005) 
found that there was no significant difference in the scores given 
by patients and raters on the SPAIQ, and Medalia et al. (2008) 
saw no difference in schizophrenic patients’ and healthy controls’ 
total scores. In Chan et al. (2008) study, neither schizophrenic and 
schizotypy patients nor healthy controls had subjective cognitive 
dysfunction scores that correlated with objective results. Indeed 
Hermann (1982) found that self-rated memory questionnaires 
given to healthy subjects in the general population bare little 
relation to actual memory ability. Therefore it seems that lack of 
insight into cognitive deficits is not just a schizophrenia-specific 
phenomenon.
Several of the studies reviewed here also included a measure of 
insight into general illness, as well as investigating cognitive insight 
by comparing subjective scores to objective tests. Five of the studies 
on the SSTICS (Chouinard et al., 2003; Stip et al., 2003; Lecardeur 
et al., 2009; Bengochea Seco et al., 2010; Johnson et al., 2011) looked 
at the relationship between SSTICS total scores and insight by use of 
the scale to assess unawareness of mental disorder (SUMD; Amador 
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Authors Schizophrenia patients Scale Objective tests Correlation
Medalia et al. 
(2008)
71 schizophrenic in and 
outpatients, 43 healthy 
controls, USA
MIC-SR BACS No correlation
Medalia and Thysen 
(2008)
75 schizophrenic in and 
outpatients, USA
MIC-CR BACS No correlation between subsets or total score
Medalia and Thysen 
(2010)
71 schizophrenic in and 
outpatients, USA
MIC-CR BACS No correlation between subsets or total score
Medalia and Lim, 
(2004)
185 schizophrenia/
schizoaffective outpatients, 
USA
WCS WCS Correlation between the clients’ ratings of their cognition and 
the WCS objective scores were only significant on verbal 
memory (rho = 0.15, p < 0.05)
Keefe et al. (2006) 60 schizophrenic inpatients, 
USA
SCoRS BACS No correlation with patients’ awareness
Ehman et al. (2007) 60 psychotic patients-
inpatients, outpatients and a 
specialized residential care 
facility, Canada
PPFS WMS, COWAT, 
TMT
No correlation with total score (item on ability to carry out 
conversations correlated with paragraph recall test, r = −0.22, 
p < 0.05)
Mass (2000) 114 schizophrenic in and 
outpatients, Germany
ESI CPT, SAT, RT Correlation first episode patients with all subscales and CPT 
response bias (ESI-AS r = −0.28, p < 0.1, ESI-IR r = −0.43, 
p < 0.01, ESI-AU r = −0.43, p < 0.01, ESI-DP r = −0.35, p < 0.05) 
and SAT eight letter condition left visual field. (ESI-AS r = −0.28, 
p < 0.1, ESI-IR r = −0.29, p < 0.1, ESI-AU r = −0.48, p < 0.001, 
ESI-DP r = −0.30, p < 0.01) no correlation for negative symptom 
group
Mass et al. (2005) 100 schizophrenic inpatients, 
Germany
ESI CPT, WCST, TMT, 
digit symbol and 
digit span from 
WAIS-R, NSS 
scale, VF
Correlation only in recent onset schizophrenia, strongest for 
verbal fluency (ESI-AS r = −0.34, p < 0.05, ESI-AU r = −0.48, 
p < 0.01, ESI-IR r = −0.57 , p < 0.001, ESI-DP r = −0.47 , p < 0.01), 
TMT-part B (ESI-AS r = 0.20, p > 0.1, ESI-AU r = 0.42, p < 0.01, 
ESI-IR r = 0.45, p < 0.01, ESI-DP r = 0.38, p < 0.01) and 
non-perseverative errors on WCST (ESI-AS r = 0.24, p > 0.1, 
ESI-AU r = 0.44, p < 0.01, ESI-IR r = 0.37 , p < 0.05, ESI-DP 
r = 0.42, p < 0.01)
Moritz et al. (2004) 53 schizophrenia spectrum 
disorder inpatients, Germany
FEDA AVLT, RBMT, test 
d2, TAP , TMT
No correlation
López-Luengo and 
Vásquez (2005)
24 schizophrenic outpatients, 
Spain
SPAIQ CPT, TMT, PASAT  No correlation with percentage improvement of each task and 
SPAIQ score
Chan et al. (2008) 36 schizophrenic inpatients, 
34 schizoptypic college 
students, 28 healthy 
controls, China
PRMQ
DEX
PMT, WMS-R, 
WCST
No correlation
van den Bosch and 
Rombouts (1998)
21 schizophrenic inpatients, 
Netherlands
TAS CPT No correlation 
van den Bosch and 
Rozendaal (1998)
21 Schizophrenic and 
schizoaffective psychotic 
inpatients, Netherlands
FCQ Eye tracking 
(SPEM), CNV-Fz 
and Cz, RT
Correlation in recovery phase but not during the psychotic 
episodes (SPEM r = 0.66, p < 0.01, CNV-Fz r = 0.53, p < 0.01, 
CNV-(Fz-Cz) r = 0.44, p < 0.05, RT r = 0.58, p < 0.01)
Cuesta et al. (1996) 32 schizophrenic inpatients, 
Spain
FCQ Edinburg test, 
MMS, WAIS, TMT, 
RCF , Bender’s 
visual-motor test, 
neurological signs
Correlation, after Bonferroni correction of WAIS (vocabulary 
r = 0.67 , p ≤ 0.001, digit span r = 0.60, p ≤ 0.01, block design 
r = 0.74, p ≤ 0.001), Bender’s test r = 0.43, p ≤ 0.05, RCF-copy 
r = 0.51, p ≤ 0.01, and TMT form A r = 0.72, p ≤ 0.001, 
B r = 0.77 , p ≤ 0.001.
(Continued)
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(1984)
24 schizophrenic inpatients, 
UK
FCQ WAIS, RT and CRT 
Tasks
No correlation 
Donohoe et al. 
(2009)
51 schizophrenic outpatients, 
UK
CFQ WAIS-III, WMS-III, 
CANTAB
Correlation (p <  0.05) for patients with intact insight with 
several tests of general cog and episodic memory function 
(WTAR r = −0.48, WAIS vocabulary r = −0.41, WMS logical 
memory I r = -0.45, WMS Logical Memory II r = −0.37 , WMS 
faces I r = 0.39, WMS faces II r = 0.42) no correlation for 
patients with impaired clinical insight
Johnson et al. 
(2009)
105 schizophrenic 
outpatients, Tunisia
SSTICS 
(SACCS)
PANSS No correlation with total score and the cognitive five factor 
model of PANSS
Johnson et al. 
(2011)
104 schizophrenic 
outpatients, Tunisia
SSTICS 
(SACCS)
The tunisian 
cognitive battery 
for patients with 
schizophrenia
No correlation
Zhornitsky et al. 
(2011)
81, schizophrenia, 
schizoaffective or 
schizophreniform disorder 
outpatients
SSTICS CANTAB No correlation 
Chouinard et al. 
(2003)
27 schizophrenic outpatients, 
Canada
SSTICS RBANS No correlation
Prouteau et al. 
(2004)
73 schizophrenic outpatients, 
Canada
SSTICS CANTAB 
visuo-spatial tests
Correlation for attention section of SSTICS with explicit 
memory (B = −2.61, Rp = −0.31, p = 0.01) and planning tasks 
(B = −2.31, Rp = −0.27 , p = 0.02) and executive functioning 
section with the explicit memory task (B = −3.23, Rp = −0.37 , 
p = 0.002)
Potvin et al. (2005) 76 schizophrenic or 
schizoaffective outpatients, 
Canada
SSTICS CANTAB Correlation in two stages of paired associates learning task 
(r = −0.372, p = 0.017 and r = −0.361, p = 0.02)
Hake et al. (2007)  20 schizophrenic or 
schizoaffective outpatients, 
USA
SSTICS WCST Correlation with non-learners group had highest executive 
functioning scores on SSTICS [t (df = 18) = 2.29, p = 0.03]
Lecardeur et al. 
(2009)
176 schizophrenia, 
schizoaffective or delusional 
disorder outpatients, Canada
SSTICS Cognition section 
of PANSS
Correlation (r = 0.338, p = 0.004)
Stip et al. (2003) 114, schizophrenia, 
schizophreniform, 
schizoaffective outpatients, 
Canada
SSTICS COWAT, RAVLT, 
TMT
Correlation with explicit memory measure (r = −0.224, 
p = 0.0009)
Bengochea Seco 
et al. (2010)
46 schizophrenic outpatients, 
Spain
SSTICS  Cognitive factor 
component of 
PANSS. barcelona 
battery
Correlation with barcelona battery subtests and SSTICS daily 
living factor (r = 0.612; p < 0.05) and SSTICS total score with 3 
subtests-(direct digits r = −0.385, p < 0.05, “P”-words 
r = −0.325, p < 0.01, Key numbers r = −0.346, p < 0.01) no 
correlation which PANSS
AVLT, auditory verbal learning test; BACS, brief assessment of cognition in schizophrenia; BVMT, Bender’s visual-motor test; CANTAB, Cambridge neurop-
sychological test automated battery; CNV-Fz, contingent negative variation-frontal midline position; CNV Cz, contingent negative variation, central midline 
position; COWAT, controlled oral word association test; CPT, continuous performance task; CRT, choice reaction time; MMS, mini-mental state; NSS Scale, 
neurological soft signs scale; PASAT, paced auditory serial addition task; PMT, prospective memory tasks; RAVLT, Rey auditory verbal learning test; RBANS, 
repeatable battery for assessment of neuropsychological status; RBMT, rivermead behavioral memory test; RCF , Rey’s complex figure; RT, reaction time; 
SACCS, self-assessment scale of cognitive complaints in schizophrenia, now called the SSTICS tunisian arabic version (SSTICS_tun_arab); SAT, span of 
apprehension task; SPEM, smooth pursuit eye movements; TAP , test battery for the assessment of attentional dysfunction; TMT, trail making test; VF , 
verbal fluency; WAIS, Wechsler adult intelligence scale; WAIS-III, Wechsler adult intelligence scale, 3rd edition; WAIS-R, Wechsler adult intelligence scale, 
revised; WCS, work-readiness cognitive screen; WCST, Wisconsin card-sorting test; WMS-III, Wechsler memory scale 3rd edition; WTAR, Wechsler test of 
adult reading.
Table 2 | Continued
Authors Schizophrenia patients Scale Objective tests Correlation
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had significantly higher complaint scores on the FCQ, however it 
must be noted that there were only six females from a small sam-
ple of just 32 patients. Similar under representation of females is 
seen in most of the other studies in this review, with only van den 
Bosch and Rombouts (1998) having an equal number of males and 
females in their study.
Another potential limitation of this review is that within studies, 
results from objective and subjective tests of cognitive dysfunction 
were not compared in a domain specific fashion. This generalizes 
the findings from the subjective and objective tests and may have 
lead to a masking of associations in particular areas. In a num-
ber of papers, this information was simply not included, and the 
importance of this is demonstrated by results from the SSTICS in 
particular, which suggest that the relationship between subdivi-
sions of cognition on subjective scales and their corresponding 
areas on objective tests is not necessarily straight forward. Stip et al. 
(2003) pointed out that in the cognitive domain of memory; only 
the global SSTICS score was reliable. In addition, Prouteau et al. 
(2004) found that although there was no correlation with objective 
memory dysfunction and memory complaints, the former was cor-
related with attention complaints and objective executive function-
ing scores, and that subjective complaints of executive functioning 
were correlated with objective memory scores.
This discrepancy between the cognitive performance of execu-
tive functioning and the subject’s perception of it, could suggest a 
malfunction of the control function of the metacognitive system. 
Indeed, the same function of “control” that allows good planning. 
The discrepancy between perception of memory deficits and objec-
tive memory scores, also suggests a dysfunction of the monitoring 
process that informs the metacognitive system on the state of the 
cognitive system.
The gap between objective and the subjective cognitive con-
structs could be the long term result of a malfunction in bottom-
up monitoring which collects information on cognitive tasks in 
order to supply and enrich the “model” of the cognitive system 
contained in the metacognitive system. In fact Stip et al. (2003) 
noted that factorial grouping based on the responses of patients 
with schizophrenia differed from that worked out from cognitive 
neuropsychology models. Thus, elements usually placed in the field 
of memory, could find themselves in that of attention, according 
to patient perceptions.
Further research
Due to the aforementioned correlation with poor insight, the 
potential for aiding medication compliance and thus overall patient 
outcome is immense if there is indeed greater insight of cognitive 
impairments in schizophrenia compared to the other domains of 
insight into this illness. We can imagine that adherence to the recent 
developments in cognitive enhancing pharmacological and psycho-
logical treatments may also suffer from poor insight, but before 
more is known on the complex issue of insight in schizophrenia, it 
is reassuring to learn that Medalia et al. (2009) found that patients 
who participated in a short psycho-educational therapy called Brain 
check that taught them about cognitive dysfunction in mental ill-
ness, had more self-awareness about their own cognitive deficits 
than those who had not participated.
originally used to describe patients with prefrontal cortical dam-
age. Patients with prefrontal lesions typically display less concern 
and a lack of regulation and control of their behavior, leading to 
abnormalities in self-awareness. Indeed Langevin and Legal (1999) 
drew a parallel with frontal lobe dysfunction and schizophrenia in 
terms of metacognition and we can postulate that it is a malfunction 
of the control function of the metacognitive system as described 
by Frith (1992) that can lead to a lack of self-awareness about a 
cognitive dysfunction, distinct from the traditional, and less specific 
term of insight.
A number of studies have used the metacognition assessment 
scale (MAS; Semerari et al., 2003) to further understand the rela-
tionship between metacognition, neurocognition, and insight. 
Lysaker et al. (2008) found links with the MAS and an executive 
function tool, and Lysaker et al. (2011) demonstrated significant 
links with the SUMD insight scale. Lysaker et al. (2005) saw that 
understanding of one’s own mind correlated with better neuro-
cognitive functioning across a number of domains, especially verbal 
memory, as well as being associated with less emotional withdrawal 
in the form of a greater depressed mood. This highlights a potential 
disadvantage of having greater metacognitive and neuro-cognitive 
function, in that patients experience the pain of having their ill-
ness to a greater degree. However, the complexity of the situation 
is revealed in that although better metacognition is linked with 
improved treatment outcomes (Roncone et al., 2002), it is also 
linked with more depression as mentioned above, where Sands and 
Harrow (1999) found that having a co-morbid diagnosis of depres-
sion with schizophrenia leads to an overall poorer patient outcome.
Limitations
One of the major limitations of this review is the heterogeneity 
in the target population, style, length, and cognitive areas cov-
ered by the scales used to assess subjective cognitive dysfunction 
in schizophrenia. There is also a bias in the numbers of studies 
using the SSTICS and several also have small sample sizes, which 
all together limit their reliability and ability for generalization. The 
argument of ecological validity of objective cognition tests must 
also be considered, as the laboratory settings and tests are very dif-
ferent from the day to day environment of the patient. In addition, 
the psychometric properties of the subjective measures should be 
questioned as the reliability and validity of each scale is not always 
known and these limitations can in turn give a false impression 
of the actual links between subjective and objective measures of 
cognitive dysfunction in schizophrenia.
There is also the issue of patient populations differing between 
studies, for example in medications, chronicity of illness, inpatients 
or outpatients, and the country where the study was conducted, 
which could all generate potential confounding factors. Another 
limitation is the unequal distribution and a general lack of focus 
on the gender of patients. It is well established that there are a 
number differences in male and female schizophrenic patients, 
such as symptomatology (Hafner, 2003), where males generally 
have more negative symptoms and females display more affective 
symptoms. There are also differences in IQ (Flor-Henry, 1985) and 
brain anatomy (Goldstein et al., 2001) and even insight into clini-
cal symptoms (Grossman et al., 2008), which could also have an 
effect on cognition and the subjective perception of dysfunction in 
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